KR20100108112A - Hangover recovery drink comprising extracts of hericium erinaceum - Google Patents
Hangover recovery drink comprising extracts of hericium erinaceum Download PDFInfo
- Publication number
- KR20100108112A KR20100108112A KR1020090026609A KR20090026609A KR20100108112A KR 20100108112 A KR20100108112 A KR 20100108112A KR 1020090026609 A KR1020090026609 A KR 1020090026609A KR 20090026609 A KR20090026609 A KR 20090026609A KR 20100108112 A KR20100108112 A KR 20100108112A
- Authority
- KR
- South Korea
- Prior art keywords
- extract
- hangover
- hours
- mushroom
- alcohol
- Prior art date
Links
- 239000000284 extract Substances 0.000 title claims abstract description 55
- 206010019133 Hangover Diseases 0.000 title claims abstract description 42
- 240000000588 Hericium erinaceus Species 0.000 title abstract description 4
- 235000007328 Hericium erinaceus Nutrition 0.000 title abstract description 4
- 238000011084 recovery Methods 0.000 title 1
- 238000010438 heat treatment Methods 0.000 claims abstract description 39
- 239000002904 solvent Substances 0.000 claims abstract description 32
- 238000002156 mixing Methods 0.000 claims abstract description 17
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 14
- 238000000034 method Methods 0.000 claims abstract description 13
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 claims abstract description 11
- 235000015468 Lycium chinense Nutrition 0.000 claims abstract description 9
- 235000003261 Artemisia vulgaris Nutrition 0.000 claims abstract description 8
- 229920002683 Glycosaminoglycan Polymers 0.000 claims abstract description 5
- 235000001674 Agaricus brunnescens Nutrition 0.000 claims description 59
- 238000000605 extraction Methods 0.000 claims description 37
- 241000282988 Capreolus Species 0.000 claims description 35
- 235000005187 Taraxacum officinale ssp. officinale Nutrition 0.000 claims description 14
- 244000241838 Lycium barbarum Species 0.000 claims description 11
- 235000015459 Lycium barbarum Nutrition 0.000 claims description 11
- 239000000203 mixture Substances 0.000 claims description 9
- 230000008030 elimination Effects 0.000 claims description 6
- 238000003379 elimination reaction Methods 0.000 claims description 6
- 239000006228 supernatant Substances 0.000 claims description 6
- 235000009051 Ambrosia paniculata var. peruviana Nutrition 0.000 claims description 5
- 235000003097 Artemisia absinthium Nutrition 0.000 claims description 5
- 240000001851 Artemisia dracunculus Species 0.000 claims description 5
- 235000017731 Artemisia dracunculus ssp. dracunculus Nutrition 0.000 claims description 5
- 239000001138 artemisia absinthium Substances 0.000 claims description 5
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 claims description 5
- 241000254173 Coleoptera Species 0.000 claims description 3
- 240000001949 Taraxacum officinale Species 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 36
- 102000007698 Alcohol dehydrogenase Human genes 0.000 abstract description 23
- 108010021809 Alcohol dehydrogenase Proteins 0.000 abstract description 23
- 108010081577 aldehyde dehydrogenase (NAD(P)+) Proteins 0.000 abstract description 18
- 235000003826 Artemisia Nutrition 0.000 abstract 1
- 244000241872 Lycium chinense Species 0.000 abstract 1
- 244000168667 Pholiota nameko Species 0.000 abstract 1
- 235000014528 Pholiota nameko Nutrition 0.000 abstract 1
- 241000691199 Taraxacum platycarpum Species 0.000 abstract 1
- 244000030166 artemisia Species 0.000 abstract 1
- 235000009052 artemisia Nutrition 0.000 abstract 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 47
- 235000019441 ethanol Nutrition 0.000 description 42
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 22
- 235000000346 sugar Nutrition 0.000 description 18
- 235000001014 amino acid Nutrition 0.000 description 17
- 229940024606 amino acid Drugs 0.000 description 17
- 150000001413 amino acids Chemical class 0.000 description 17
- BAWFJGJZGIEFAR-DQQFMEOOSA-N [[(2r,3s,4r,5r)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2s,3r,4s,5s)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphate Chemical compound NC(=O)C1=CC=C[N+]([C@@H]2[C@H]([C@@H](O)[C@H](COP([O-])(=O)O[P@@](O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 BAWFJGJZGIEFAR-DQQFMEOOSA-N 0.000 description 13
- 241000245665 Taraxacum Species 0.000 description 12
- 230000001965 increasing effect Effects 0.000 description 11
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 description 10
- 229910052500 inorganic mineral Inorganic materials 0.000 description 10
- 239000011707 mineral Substances 0.000 description 10
- 235000010755 mineral Nutrition 0.000 description 10
- 239000007787 solid Substances 0.000 description 10
- 241000218645 Cedrus Species 0.000 description 8
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 8
- 238000002835 absorbance Methods 0.000 description 8
- 239000004480 active ingredient Substances 0.000 description 8
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 8
- 235000003599 food sweetener Nutrition 0.000 description 8
- 230000004060 metabolic process Effects 0.000 description 8
- 239000003765 sweetening agent Substances 0.000 description 8
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 7
- 235000013361 beverage Nutrition 0.000 description 7
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 7
- BOPGDPNILDQYTO-NNYOXOHSSA-N nicotinamide-adenine dinucleotide Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 BOPGDPNILDQYTO-NNYOXOHSSA-N 0.000 description 7
- 235000001968 nicotinic acid Nutrition 0.000 description 7
- 239000011664 nicotinic acid Substances 0.000 description 7
- 229960003512 nicotinic acid Drugs 0.000 description 7
- 102000004190 Enzymes Human genes 0.000 description 6
- 108090000790 Enzymes Proteins 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 239000000470 constituent Substances 0.000 description 6
- 238000001035 drying Methods 0.000 description 6
- 229940088598 enzyme Drugs 0.000 description 6
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 6
- 235000010374 vitamin B1 Nutrition 0.000 description 6
- 239000011691 vitamin B1 Substances 0.000 description 6
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 5
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 5
- 239000008103 glucose Substances 0.000 description 5
- 239000004615 ingredient Substances 0.000 description 5
- 210000004185 liver Anatomy 0.000 description 5
- 235000018102 proteins Nutrition 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 150000008163 sugars Chemical class 0.000 description 5
- MSWZFWKMSRAUBD-GASJEMHNSA-N 2-amino-2-deoxy-D-galactopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@H](O)[C@@H]1O MSWZFWKMSRAUBD-GASJEMHNSA-N 0.000 description 4
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 4
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- 230000003078 antioxidant effect Effects 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 229960002442 glucosamine Drugs 0.000 description 4
- QKFJKGMPGYROCL-UHFFFAOYSA-N phenyl isothiocyanate Chemical compound S=C=NC1=CC=CC=C1 QKFJKGMPGYROCL-UHFFFAOYSA-N 0.000 description 4
- 229940107700 pyruvic acid Drugs 0.000 description 4
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 3
- PNNNRSAQSRJVSB-SLPGGIOYSA-N Fucose Natural products C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C=O PNNNRSAQSRJVSB-SLPGGIOYSA-N 0.000 description 3
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 3
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 3
- SHZGCJCMOBCMKK-DHVFOXMCSA-N L-fucopyranose Chemical compound C[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@@H]1O SHZGCJCMOBCMKK-DHVFOXMCSA-N 0.000 description 3
- 229930003451 Vitamin B1 Natural products 0.000 description 3
- 235000003704 aspartic acid Nutrition 0.000 description 3
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 3
- 210000004556 brain Anatomy 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 239000005515 coenzyme Substances 0.000 description 3
- 230000035622 drinking Effects 0.000 description 3
- 201000006549 dyspepsia Diseases 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 229930182830 galactose Natural products 0.000 description 3
- 230000002496 gastric effect Effects 0.000 description 3
- 235000013922 glutamic acid Nutrition 0.000 description 3
- 239000004220 glutamic acid Substances 0.000 description 3
- 208000024798 heartburn Diseases 0.000 description 3
- 239000004310 lactic acid Substances 0.000 description 3
- 235000014655 lactic acid Nutrition 0.000 description 3
- 210000005229 liver cell Anatomy 0.000 description 3
- 230000003647 oxidation Effects 0.000 description 3
- 238000007254 oxidation reaction Methods 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 229960003495 thiamine Drugs 0.000 description 3
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 3
- 229940088594 vitamin Drugs 0.000 description 3
- 229930003231 vitamin Natural products 0.000 description 3
- 235000013343 vitamin Nutrition 0.000 description 3
- 239000011782 vitamin Substances 0.000 description 3
- 235000019164 vitamin B2 Nutrition 0.000 description 3
- 239000011716 vitamin B2 Substances 0.000 description 3
- 208000019901 Anxiety disease Diseases 0.000 description 2
- 240000006891 Artemisia vulgaris Species 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 2
- 206010012289 Dementia Diseases 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 2
- 108010025020 Nerve Growth Factor Proteins 0.000 description 2
- 102000015336 Nerve Growth Factor Human genes 0.000 description 2
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 2
- 229930003471 Vitamin B2 Natural products 0.000 description 2
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 2
- IKHGUXGNUITLKF-XPULMUKRSA-N acetaldehyde Chemical compound [14CH]([14CH3])=O IKHGUXGNUITLKF-XPULMUKRSA-N 0.000 description 2
- -1 acidulant Substances 0.000 description 2
- 235000004279 alanine Nutrition 0.000 description 2
- 230000001476 alcoholic effect Effects 0.000 description 2
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 230000036506 anxiety Effects 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 239000006227 byproduct Substances 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 239000001569 carbon dioxide Substances 0.000 description 2
- 229910002092 carbon dioxide Inorganic materials 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- VFPFQHQNJCMNBZ-UHFFFAOYSA-N ethyl gallate Chemical compound CCOC(=O)C1=CC(O)=C(O)C(O)=C1 VFPFQHQNJCMNBZ-UHFFFAOYSA-N 0.000 description 2
- 230000035784 germination Effects 0.000 description 2
- 238000000227 grinding Methods 0.000 description 2
- 235000012907 honey Nutrition 0.000 description 2
- 229910010272 inorganic material Inorganic materials 0.000 description 2
- 239000011147 inorganic material Substances 0.000 description 2
- 235000005772 leucine Nutrition 0.000 description 2
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 2
- 210000004877 mucosa Anatomy 0.000 description 2
- 229940053128 nerve growth factor Drugs 0.000 description 2
- KHPXUQMNIQBQEV-UHFFFAOYSA-N oxaloacetic acid Chemical compound OC(=O)CC(=O)C(O)=O KHPXUQMNIQBQEV-UHFFFAOYSA-N 0.000 description 2
- 235000015206 pear juice Nutrition 0.000 description 2
- 229940117953 phenylisothiocyanate Drugs 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 229960002477 riboflavin Drugs 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 150000003722 vitamin derivatives Chemical class 0.000 description 2
- 235000010447 xylitol Nutrition 0.000 description 2
- 239000000811 xylitol Substances 0.000 description 2
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 2
- 229960002675 xylitol Drugs 0.000 description 2
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- LQIAZOCLNBBZQK-UHFFFAOYSA-N 1-(1,2-Diphosphanylethyl)pyrrolidin-2-one Chemical compound PCC(P)N1CCCC1=O LQIAZOCLNBBZQK-UHFFFAOYSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- 230000002407 ATP formation Effects 0.000 description 1
- 208000022309 Alcoholic Liver disease Diseases 0.000 description 1
- 208000007848 Alcoholism Diseases 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 208000014644 Brain disease Diseases 0.000 description 1
- 206010008096 Cerebral atrophy Diseases 0.000 description 1
- 241001233914 Chelidonium majus Species 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 206010012335 Dependence Diseases 0.000 description 1
- 239000004262 Ethyl gallate Substances 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- 208000007882 Gastritis Diseases 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 208000004547 Hallucinations Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 240000005979 Hordeum vulgare Species 0.000 description 1
- 235000007340 Hordeum vulgare Nutrition 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 208000013016 Hypoglycemia Diseases 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 206010027940 Mood altered Diseases 0.000 description 1
- 229910003251 Na K Inorganic materials 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 206010037180 Psychiatric symptoms Diseases 0.000 description 1
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 206010039203 Road traffic accident Diseases 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 229910009369 Zn Mg Inorganic materials 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 125000000218 acetic acid group Chemical class C(C)(=O)* 0.000 description 1
- 201000007930 alcohol dependence Diseases 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 108090000637 alpha-Amylases Proteins 0.000 description 1
- 102000004139 alpha-Amylases Human genes 0.000 description 1
- 229940024171 alpha-amylase Drugs 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 230000003444 anaesthetic effect Effects 0.000 description 1
- 238000005571 anion exchange chromatography Methods 0.000 description 1
- 230000002075 anti-alcohol Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 239000000729 antidote Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 108010019077 beta-Amylase Proteins 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000004641 brain development Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 208000015114 central nervous system disease Diseases 0.000 description 1
- 210000004720 cerebrum Anatomy 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000023652 chronic gastritis Diseases 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- HHEAADYXPMHMCT-UHFFFAOYSA-N dpph Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1[N]N(C=1C=CC=CC=1)C1=CC=CC=C1 HHEAADYXPMHMCT-UHFFFAOYSA-N 0.000 description 1
- 208000000718 duodenal ulcer Diseases 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 230000037149 energy metabolism Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- 235000020774 essential nutrients Nutrition 0.000 description 1
- 235000019277 ethyl gallate Nutrition 0.000 description 1
- 230000005281 excited state Effects 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 201000005917 gastric ulcer Diseases 0.000 description 1
- 239000007986 glycine-NaOH buffer Substances 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 238000007602 hot air drying Methods 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 230000007510 mood change Effects 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- FEMOMIGRRWSMCU-UHFFFAOYSA-N ninhydrin Chemical compound C1=CC=C2C(=O)C(O)(O)C(=O)C2=C1 FEMOMIGRRWSMCU-UHFFFAOYSA-N 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000011368 organic material Substances 0.000 description 1
- 239000005416 organic matter Substances 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000006479 redox reaction Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000002207 retinal effect Effects 0.000 description 1
- 208000019116 sleep disease Diseases 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- FQENQNTWSFEDLI-UHFFFAOYSA-J sodium diphosphate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]P([O-])(=O)OP([O-])([O-])=O FQENQNTWSFEDLI-UHFFFAOYSA-J 0.000 description 1
- 229940048086 sodium pyrophosphate Drugs 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000002798 spectrophotometry method Methods 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 235000019818 tetrasodium diphosphate Nutrition 0.000 description 1
- 239000001577 tetrasodium phosphonato phosphate Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 230000004102 tricarboxylic acid cycle Effects 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 230000001018 virulence Effects 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 238000003809 water extraction Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/38—Other non-alcoholic beverages
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/52—Adding ingredients
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/334—Foods, ingredients or supplements having a functional effect on health treating the effects of consuming alcohol, narcotics or other addictive behavior, e.g. treating hangover or reducing blood alcohol levels
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/20—Natural extracts
- A23V2250/208—Fungi extracts
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2300/00—Processes
- A23V2300/14—Extraction
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2300/00—Processes
- A23V2300/24—Heat, thermal treatment
Abstract
Description
본 발명은 노루궁뎅이 버섯을 이용한 숙취해소 음료에 관한 것으로서, 더욱 상세하게는 노루궁뎅이 버섯의 숙취해소를 위한 유효성분을 효과적으로 추출하여 알코올분해효소의 활성이 우수한 숙취해소 음료에 관한 것이다.The present invention relates to a hangover remedy drink using the roe deer mushroom, and more particularly, to a hangover remedy drink excellent in the activity of alcohol degrading enzyme by effectively extracting the active ingredient for the hangover of the roe deer mushroom.
알코올은 뇌의 중추를 억제, 마비시켜 섭취시 외관상 흥분한 상태를 보여주게 되는데, 의식과 동작을 억제하고 수면 및 마취 효과가 있어 스트레스를 많이 받는 현대인의 기호식품으로 자리 잡고 있다. 우리 나라의 음주문화는 경제성장과 함께 경제활동을 위한 사교에서도 큰 몫을 담당할 뿐 아니라, 현대사회로부터 오는 정신적 외로움을 달래는 문화 생활의 일부가 되고 있다.Alcohol suppresses and paralyzes the center of the brain and shows an excited state when ingested. It suppresses consciousness and movement and has a sleeping and anesthetic effect, making it a favorite food for stressed modern people. Drinking culture of our country not only plays a big part in social growth for economic activity along with economic growth, but also becomes a part of cultural life to soothe mental loneliness from modern society.
이처럼 술은 소량 섭취하면 기분전환을 위해서도 좋고 혈액순환에도 도움이 되어 건강에 유익할 수 있으나 과량을 만성적으로 섭취하면 알코올성 간질환 등 여러 가지 건강문제를 야기하게 되며, 중독증으로까지 발전할 수 있으며, 뇌 등의 중추신경계뿐 아니라 소화기관 및 간 등의 대사기관도 손상시킬 수 있어 개인의 건강을 위협하는 심각한 문제가 되고 있다. 또한, 음주로부터 비롯되는 교통사고 등의 위험은 개개인의 문제를 떠나서 사회적 문제로 되고 있으며, 이에 따라 알코올이 인체에 미치는 영향을 최소화할 수 있는 식품이나 의약품 등에 대한 요구도 증가하고 있다.Like this, drinking small amount of alcohol is good for mood change and also helps blood circulation, and it can be beneficial for health.However, excessive consumption of chronic alcohol can lead to various health problems such as alcoholic liver disease, and can lead to addiction. Not only the central nervous system, such as the brain, but also the digestive system and metabolic organs, such as the liver, which can damage the health of the individual has become a serious problem. In addition, risks such as traffic accidents resulting from drinking are becoming a social problem apart from individual problems, and accordingly, there is an increasing demand for foods and medicines that can minimize the effects of alcohol on the human body.
술을 마시면, 알코올은 식도에서 소량 흡수되고 약 10%는 위장에서 90%는 소장에서 흡수되며, 흡수된 알코올은 혈류를 따라 뇌와 간 등 신체 각 조직으로 이동하며 약 10% 정도는 소변 및 땀으로 배출되고 나머지 90%는 간에서 분해된다. After drinking alcohol, a small amount of alcohol is absorbed in the esophagus, about 10% in the stomach, 90% in the small intestine, and the absorbed alcohol moves along the bloodstream to the body and other tissues, such as the brain and liver, and about 10% is urine and sweat. The remaining 90% is broken down by the liver.
알코올 분해의 첫 단계는, 알코올분해효소(alcohol dehydrogenase, ADH)가 알코올을 산화하여 아세트알데하이드로 전환시키며, 이는 다시 아세트알데하이드분해효소(aldehyde dehydrogenase, ALDH)에 의해 산화되어 신체에 무해한 초산으로 전환시킨다. 이 초산은 다시 물과 이산화탄소로 분해되어 체외로 배출된다. 각 단계에서 산화된 NAD+ 로부터 1분자의 환원형 NADH가 생성되며, 여기서 NAD+는 조효소의 역할을 한다. 간의 알코올 탈수소효소에 의한 알코올의 대사는 그 부산물로 NADH를 생성하여 NADH/NAD+ 비를 증가시킨다. 이러한 산화환원 상태의 변화는 여러 중간단계 대사에 영향을 미치게 된다. In the first stage of alcohol degradation, alcohol dehydrogenase (ADH) oxidizes the alcohol and converts it into acetaldehyde, which in turn is oxidized by acetaldehyde dehydrogenase (ALDH) to acetic acid, which is harmless to the body. . This acetic acid is again broken down into water and carbon dioxide and released into the body. At each step, one molecule of reduced NADH is produced from the oxidized NAD +, where NAD + acts as a coenzyme. The metabolism of alcohol by alcohol dehydrogenase in the liver produces NADH as a by-product, increasing the NADH / NAD + ratio. This change in redox state affects several intermediate metabolisms.
특히, 젖산은 피루브산으로의 전환시 NAD+를 이용해야 하나 알코올 산화에 NAD+가 쓰이므로 젖산이 피루브산으로 전환되지 않고 축적되어 혈액의 pH를 떨어뜨린다. 뿐만 아니라 알코올 산화시 NADH/NAD+ 비가 증가되지만 계속적인 알코올의 산화를 위해서는 이들 비율을 정상적으로 유지시키는 것이 필요하다. 따라서 피루브산을 젖산으로 TCA 회로 내의 옥살로아세트산을 말산으로 전환시켜 이때 생성된 NAD+를 이용한다. 이러한 피루브산이나 옥살로아세트산의 부족은 포도당신생과정을 저해하여 포도당 합성이 제대로 이루어지지 못하게 하여 공복시 알코올을 섭취하면 저혈당을 초래할 수가 있다.In particular, lactic acid should use NAD + when converting to pyruvic acid, but since NAD + is used for alcohol oxidation, lactic acid does not convert to pyruvic acid and accumulates to lower blood pH. In addition, although the NADH / NAD + ratio increases during alcohol oxidation, it is necessary to maintain these ratios normally for the continuous oxidation of alcohol. Therefore, pyruvic acid is converted to lactic acid and oxaloacetic acid in the TCA cycle to malic acid is used to produce the NAD +. This lack of pyruvic acid or oxaloacetic acid inhibits the virulence process of glucose and prevents the synthesis of glucose properly, resulting in hypoglycemia when fasting alcohol is consumed.
알코올 섭취 후 나타나는 숙취 증상은 알코올 분해의 부산물인 아세트알데하이드가 분해되지 않고 오래 머물게 되면서 불쾌감, 두통, 혈압상승, 홍조, 구토 등을 유발시키는 것으로 알려져 있다. Hangover symptoms after alcohol consumption are known to cause discomfort, acetaldehyde, which is a byproduct of alcohol breakdown, causing long-term discomfort, headache, increased blood pressure, flushing, and vomiting.
대뇌와 간에 아세트알데하이드가 머무는 시간이 길어지면 신경계의 손상과 심각한 간질환이 유발되며 중추신경계이상 간성뇌장애, 대뇌위축, 알코올성 망막이상, 알코올 중독, 불안, 초조, 우울증, 수면장애, 알코올성 치매, 환청, 환시 등 심각한 신체적 문제를 발생된다.Longer stays of acetaldehyde in the cerebrum and liver cause damage to the nervous system and serious liver disease, including central nervous system disorders, hepatic brain disorders, cerebral atrophy, alcoholic retinal abnormalities, alcoholism, anxiety, anxiety, depression, sleep disorders, alcoholic dementia, Serious physical problems such as hearing and hallucinations occur.
이와 같은 숙취 증상을 감소시킬 수 있는 약물에 대한 연구는 활발히 이루어져 이미 많은 제품이 소개되어 있다. 국내에서 시판되고 있는 숙취해소용 제제로는 컨디션(제일제당), 아스파(대상), 솔표비지니스(조선무약), 여명808(그래미), 리셉션(미래바이오), 모닝케어(동아제약) 등이 있지만, 이들 중에서 혈중 알코올 농도 감소 효과에 대한 임상 실험을 거친 것은 일부에 지나지 않으며, 그 일부조차도 상용량의 거의 5배 정도를 복용해야만 효과가 나타나는 것으로 되어 있다. 그러나 이들 약물이 혈중 알코올 농도를 감소시키는 여부에 대해서는 대부분 과학적으로 검정되지 않았거나 그 감소 효과가 미미한 것으로 나타나 있다.Research into drugs that can reduce the hangover symptoms have been actively conducted, many products have already been introduced. Domestic hangover-relieving preparations include Condition (Cheil Jedang), Aspa (Target), Sol Pyo Business (Drug Free), Dawn 808 (Grammy), Reception (Future Bio), Morning Care (Dong-A) Among them, only a few have undergone clinical experiments on the effect of reducing blood alcohol levels, and even some of them are effective only when the dose is taken at about five times the normal dose. However, whether these drugs reduce blood alcohol levels has not been scientifically validated or shown to be insignificant.
그리고 대한민국 공개특허공보 제 2005-0079790호에는 노루궁뎅이버섯의 추출물을 포함하는 알코올 분해 촉진용 조성물이 개시되어 있다. And the Republic of Korea Patent Publication No. 2005-0079790 discloses a composition for promoting alcohol degradation comprising the extract of roe deer mushroom.
상기 조성물은 균사체 또는 자실체를 에탄올에 혼합한 후 상온추출시킨 추출 물로 이루어지나, 이러한 추출방법은 노루궁뎅이 버섯에 함유된 숙취해소를 위한 유효성분을 충분히 추출할 수 없거나, 추출하였다 하더라도 추출용매에 에탄올이 섞여있으므로 추출 후 에탄올을 제거하는 농축공정이 필수적이며, 다시 이들 농축물을 적당한 비율로 희석해야하는 등 여러 가지 번거롭고 비효율적인 문제점이 발생한다. The composition consists of an extract obtained by mixing the mycelium or fruiting body in ethanol and then extracted at room temperature, but this extraction method is not enough to extract the active ingredient for hangover contained in the worm mushroom, or even if extracted ethanol in the extraction solvent Because of this mixture, a concentration step of removing ethanol after extraction is essential, and various cumbersome and inefficient problems occur, such as diluting these concentrates at an appropriate ratio.
본 발명은 상술한 문제점을 개선하기 위하여 창출된 것으로서, 노루궁뎅이버섯에 함유된 숙취해소 작용이 있는 유효성분의 손실을 최소화하면서 유효성분을 최대한 추출하고자 하는 적정의 추출용매배수, 추출온도, 추출시간을 제공하여 알코올분해효소 활성과 아세트알데하이드분해효소 활성을 증가시킬 수 있는 숙취해소 음료를 제공하는 데 그 목적이 있다. The present invention has been created to improve the above-mentioned problems, extracting solvent drainage, extraction temperature, extraction time of the optimum to extract the active ingredient while minimizing the loss of the active ingredient with a hangover action contained in the roe deer mushroom The purpose of the present invention is to provide hangover-relieving beverages capable of increasing alcoholase activity and acetaldehydease activity.
상기의 목적을 달성하기 위한 본 발명의 숙취해소 음료는 민들레, 구기자, 사철쑥의 추출물과 노루궁뎅이 버섯 추출물을 포함하여 조성된 것을 특징으로 한다.Hangover releasing drink of the present invention for achieving the above object is characterized in that the composition comprising an extract of dandelion, wolfberry, wormwood and locust mushroom extract.
상기 노루궁뎅이 버섯 추출물은 노루궁뎅이버섯에 대한 추출용매의 중량비가 30 내지 60이 되도록 혼합한 후 65 내지 85℃에서 16 내지 24시간 동안 가열하여 추출한 것을 특징으로 한다.The roe deer mushroom extract is characterized in that the extraction by mixing so that the weight ratio of the extraction solvent to the
상기 추출용매는 물에 엿기름을 풀어서 우려낸 후 상층액을 취하여 얻어진 것을 특징으로 한다.The extraction solvent is characterized by being obtained by taking off the malt in water and taking out the supernatant.
상기 숙취해소 음료는 뮤코다당체를 함유하는 맛 버섯 추출물을 더 포함하는 것을 특징으로 한다.The hangover drink is characterized in that it further comprises a taste mushroom extract containing the mucopolysaccharide.
상술한 바와 같이 본 발명에 의하면 추출용매 배수 및 추출온도, 추출시간을 제시함으로써 노루궁뎅이 버섯의 유효성분을 최대한 추출할 수 있다. As described above, according to the present invention, the active ingredient of the roe deer mushroom can be extracted as much as possible by presenting the extraction solvent drainage, the extraction temperature, and the extraction time.
본 발명에서 제시된 노루궁뎅이 추출기술에 의하면 알코올디하이드로겐에이스(ADH)와 아세트알데하이드디하이드로겐에이스(ALDH) 활성이 시중 숙취해소 음료보다 1.5~2배 더 높아 알코올 대사를 촉진시켜 혈중 알코올 농도를 효과적으로 감소시킬 수 있다. According to the roe deer extract according to the present invention, alcohol dihydrogen ace (ADH) and acetaldehyde dihydrogen ace (ALDH) activity is 1.5 to 2 times higher than that of commercial hangover beverages to promote alcohol metabolism, thereby promoting blood alcohol concentration. Can be effectively reduced.
또한, 구기자, 민들레, 사철쑥은 알코올로부터 간세포를 보호하고, 맛 버섯은 위장점막을 도포함으로써 알코올 흡수 방지 또는 속쓰림을 예방할 수 있다. In addition, goji berry, dandelion, cedars can protect the liver cells from alcohol, taste mushrooms can be applied to the gastrointestinal mucosa to prevent alcohol absorption or heartburn.
이하, 본 발명의 노루궁뎅이 버섯을 이용한 숙취해소 음료에 대해서 구체적으로 설명한다. Hereinafter, the hangover elimination drink using the roe deer mushroom of the present invention will be described in detail.
본 발명의 숙취해소 음료는 노루궁뎅이 버섯 추출물을 주재로 하고, 여기에 민들레, 구기자, 사철쑥의 추출물을 포함하여 조성된다. Hangover elimination drink of the present invention is mainly composed of the extract of the Roe deer beetle, it is composed by including the extract of dandelion, wolfberry, wormwood.
노루궁뎅이 버섯(Hericium erinaceum)은 항산화, 항암, 위궤양, 십이지장궤양, 만성위염치료, 면역력증강 효과가 있으며, 신경성장인자(NGF)를 함유하여 두뇌발달 및 치매예방에 효과가 있는 것으로 알려져 있다. Roe deer mushroom ( Hericium erinaceum ) has antioxidant, anti-cancer, gastric ulcer, duodenal ulcer, chronic gastritis treatment, immune enhancing effect, and is known to be effective in preventing brain development and dementia by containing nerve growth factor (NGF).
노루궁뎅이 버섯은 자연에서 채취되거나 통상적으로 인공배양된 것일 수 있다. 노루궁뎅이 버섯은 60℃에서 24 내지 48시간 동안 열풍건조시켜 수분함량이 3~4%인 것을 이용한다. Roe deer mushrooms may be taken from nature or commonly artificially cultured. Roe deer mushroom is hot-air-dried at 60 ° C. for 24 to 48 hours to use a moisture content of 3 to 4%.
상기와 같이 건조시킨 노루궁뎅이 버섯의 일반성분, 무기질 및 비타민은 하기의 표 1과 같다. 일반분석은 A.O.A.C 방법을 이용하였고, 무기질은 ICP-emission spectrophotometry(agilent 7500 series)로 분석하였다. 비타민은 식품공전 고시 방법을 이용하였다.General ingredients, minerals and vitamins of the dried roe deer mushroom as described above are shown in Table 1 below. General analysis was performed using A.O.A.C method, and minerals were analyzed by ICP-emission spectrophotometry (agilent 7500 series). Vitamin was used in the food disclosure notice method.
일반성분
(g/100g건조중)
General ingredient
(g / 100g drying)
무기질
(g/100g건조중)
Mineral
(g / 100g drying)
비타민
(mg/100g건조중)
vitamin
(mg / 100g during drying)
그리고 노루궁뎅이 버섯에 함유된 유리당 및 구성당은 하기 표 2와 같다. 유리당 및 구성당 분석은 high-pH anion exchange chromatography with pulsed amperometric detection(HPAEC-PAD)을 이용하여 분석하였으며, 표준당은 Sigma사에서 구입한 fucose, glucose, galactose, mannose, glucosamine, galactosamine으로 하였다. And the free sugar and constituent sugar contained in the roe deer mushroom are shown in Table 2 below. Free and constituent sugars were analyzed using high-pH anion exchange chromatography with pulsed amperometric detection (HPAEC-PAD). Standard sugars were fucose, glucose, galactose, mannose, glucosamine and galactosamine purchased from Sigma.
그리고 노루궁뎅이 버섯에 함유된 구성아미노산(mg/100g)은 하기 표 3과 같이 나타났다. 구성 아미노산 조성은 Pico·Tag 아미노산 분석방법에 따라 버섯추출물을 취해 Phenylisothiocyanate(PITC)로 유도체화시킨 후 HPLC(Model, Waters Co., USA)로 분석하였다. 아미노산 표준물질은 amino acid general standard(Sigma Co,. USA)를 사용하였다.And the constituent amino acid (mg / 100g) contained in the Roe deer mushroom was shown in Table 3 below. The amino acid composition was analyzed by HPLC (Model, Waters Co., USA) after extracting mushroom extract according to Pico-Tag amino acid analysis method, derivatizing with Phenylisothiocyanate (PITC). Amino acid standard was used as amino acid general standard (Sigma Co ,. USA).
상기의 표 1 내지 표 3에 나타낸 것처럼 노루궁뎅이버섯은 탄수화물의 구성당인 글루코스, 글루코사민, 갈락토사민, 만노스, 퓨코스, 갈락토스를 함유하며, 단백질의 구성아미노산은 글루탐산, 아스파르트산, 알라닌, 루신 등을 많이 함유하며, 무기질과 비타민 B1, B2, 특히 나이아신이 다량 함유되어 있다. As shown in Tables 1 to 3 above, the worm mushroom contains glucose, glucosamine, galactosamine, mannose, fucose, and galactose, which are constituent sugars of carbohydrates, and the amino acids of proteins are glutamic acid, aspartic acid, alanine, and leucine. It contains a lot of minerals and vitamins B1 and B2, especially niacin.
노루궁뎅이버섯의 구성성분으로서 숙취해소를 위한 유용성분으로는 글루코사민, 갈락토사민 등의 구성 단당류이며, 단백질 중 아스파르트산은 체내 NADH/NAD+ 비의 보정효과가 있어 알코올 대사에서 오는 부작용을 완화시키는 역할을 한다고 보고되어 있다.Useful components for hangover as a constituent of roe deer mushroom are constituent monosaccharides such as glucosamine and galactosamine, and aspartic acid among proteins has the effect of correcting the NADH / NAD + ratio in the body, thereby alleviating side effects from alcohol metabolism. It is reported.
또한, 알코올은 체내에서 1g 대사하면 7Kcal의 열량을 내는데 에너지 대사에 필요한 Mg, K 등 무기질과 비타민 B1, B2, 나이아신이 풍부하다. 특히 나이아신의 조효소 형태는 니코틴아미드 디뉴클레오티드(NAD)와 니코틴아미드 디뉴클레오티드 포스페이드(NADP)로서 체내의 산화-환원 반응에 참여한다. 특히 ATP를 생성하는 과정 중 열량 영양소들의 대사과정에 필수적인 조효소로 작용한다. In addition, alcohol 1g metabolism in the body to produce calories of 7Kcal, which is rich in minerals such as Mg, K, necessary for energy metabolism, vitamins B1, B2, niacin. In particular, the coenzyme form of niacin participates in the body's redox reactions as nicotinamide dinucleotide (NAD) and nicotinamide dinucleotide phosphate (NADP). In particular, it acts as a coenzyme essential for the metabolism of calorie nutrients during the production of ATP.
노루궁뎅이 버섯 추출물은 건조시킨 노루궁뎅이버섯을 추출용매에 혼합한 후 가열하여 얻어진다. 이 경우 노루궁뎅이 버섯에 대한 추출용매의 중량비가 30 내지 60이 되도록 혼합한 후 65 내지 85℃에서 16 내지 24시간 동안 가열하여 추출하는 것이 바람직하다. 추출용매로 물을 이용한다. 이외에도 통상적인 추출용매를 이용할 수 있다. The roe deer mushroom extract is obtained by mixing the dried roe deer mushroom in an extraction solvent and heating. In this case, after mixing so that the weight ratio of the extraction solvent to the roe deer mushroom is 30 to 60, it is preferable to extract by heating at 65 to 85 ℃ for 16 to 24 hours. Water is used as the extraction solvent. In addition, a conventional extraction solvent can be used.
바람직하게는 물에 엿기름이 함유된 추출용매를 이용한다. 일 예로 엿기름을 곱게 빻아 얻어진 엿기름 분말을 냉수에 풀어서 3 내지 5시간 동안 정치시킨 후 맑은 상층수만을 취하여 추출용매로 이용할 수 있다. 엿기름은 보리를 발아시킨 것으로 발아시키지 않았을 때보다 단백질, 무기질 함량에서 현저히 증가하며, 비타민 B1, B2, 나이아신의 함량은 5~7배 더 증가되는데, 이들은 인체 내에서 알코올이 여러 단계의 대사과정을 거쳐 물과 이산화탄소로 분해되기 위해 반드시 필요한 영양소들이다. 또한, 엿기름에는 전분과 단백질을 분해할 수 있는 α-아밀라제, β-아밀라제 및 프로테아제 등 많은 효소들을 함유하고 있다. 본 발명에서 추출온도는 65 내지 85℃로서, 엿기름에 함유된 효소가 활성화하기에 최적정온도는 아니지만, 추출 중에 어느 정도는 이들 효소들의 활성에 의해 노루궁뎅이버섯성분이 분해될 것으로 기대된다.Preferably, an extraction solvent containing malt in water is used. For example, the malt powder obtained by grinding the malt finely can be dissolved in cold water, left to stand for 3 to 5 hours, and then taken only as a clear supernatant can be used as an extraction solvent. Malt germination of barley is significantly increased in protein and mineral content than without germination. Vitamin B1, B2, and niacin levels are increased five to seven times higher. They are essential nutrients to be broken down into water and carbon dioxide. Malt also contains many enzymes, such as α-amylase, β-amylase and protease, which can degrade starch and protein. In the present invention, the extraction temperature is 65 to 85 ℃, although the optimum temperature for the enzyme contained in the malt is not optimal temperature, it is expected that the extract of the roe deer mushroom is decomposed by the activity of these enzymes to some extent during the extraction.
상기 노루궁뎅이버섯 추출물은 본 발명의 숙취해소 음료 중 0.1 내지 99중량%가 함유된다. The roe deer mushroom extract contains 0.1 to 99% by weight of the hangover relieving drink of the present invention.
민들레, 구기자, 사철쑥은 노루궁뎅이버섯과 함께 혼합하여 상기와 동일한 방법으로 추출할 수 있다. 가령, 노루궁뎅이 버섯 100중량부를 기준으로 민들레 15 내지 25중량부, 구기자 15 내지 25중량부, 사철쑥 7 내지 13중량부를 혼합한 혼합물에 대한 추출용매의 중량비가 30 내지 60이 되도록 혼합한 후 65 내지 85℃에서 16 내지 24시간 동안 가열하여 추출한다. 이와 달리 민들레, 구기자, 사철쑥 각각을 별도로 추출하여 맛 버섯 추출물과 혼합할 수 있다. Dandelion, gojija, celandine Wormwood can be extracted with the same method as above by mixing with the roe deer mushroom. For example, 15 to 25 parts by weight of dandelion mushroom, 15 to 25 parts by weight of goji berry, 7 to 13 parts by weight of wormwood, and mixed so that the weight ratio of the extraction solvent to 30 to 60 after mixing 65 to Extract by heating at 85 ° C. for 16-24 hours. In contrast, dandelion, wolfberry, and cedars can be separately extracted and mixed with flavored mushroom extracts.
상기 민들레와 구기자, 사철쑥은 예부터 민방과 한방에서 강장, 이뇨, 해독제 등의 약제로 사용되어 온 것으로서, 본 발명에서 노루궁뎅이 버섯을 보조하여 알코올로부터 간세포를 보호하는 역할을 할 것으로 기대된다. The dandelion and gojija, cedar mugwort has been used as a tonic, diuretic, antidote, etc. in the medicinal and herbal medicine since ancient times, in the present invention is expected to play a role in protecting liver cells from alcohol by supplementing the locust mushroom.
본 발명의 숙취해소 음료는 기능성을 강화하기 위해 뮤코다당체를 함유하는 맛 버섯 추출물을 더 포함할 수 있다. 맛 버섯 추출물에 함유된 점액물질의 뮤코다당체를 섭취하면 위벽 및 장관벽을 보호하고 알코올흡수를 방해할 것으로 기대되며, 숙취증상인 속쓰림을 예방 또는 치료할 것으로 기대된다. 맛 버섯 추출물은 맛 버섯 자실체를 추출용매와 혼합한 후 분쇄기로 갈아서 원심분리시켜 얻어진 상층액을 이용한다. 맛 버섯 추출물은 숙취해소 음료 전체 중량에서 5 내지 50중량% 함유되는 것이 바람직하다. Hangover drink of the present invention may further include a taste mushroom extract containing mucopolysaccharide to enhance functionality. Ingestion of mucopolysaccharides of mucus in the mushroom extracts is expected to protect the gastric and intestinal walls, prevent alcohol absorption, and prevent or treat heartburn, a hangover symptom. The taste mushroom extract uses the supernatant obtained by mixing the taste mushroom fruit body with the extraction solvent and grinding the grinder. Flavored mushroom extract is preferably contained 5 to 50% by weight of the total weight of the hangover.
그리고 본 발명의 숙취해소음료는 산미료 및 감미료가 더 첨가될 수 있다. 산미료로서 구연산, 매실엑기스 등이 첨가될 수 있으며, 감미료로서 자일리톨, 벌꿀, 농축 배즙이 첨가될 수 있다. 상기 감미료 외에도 통상의 음료와 같이 여러 가지 감미제가 사용될 수 있음은 물론이다. 숙취해소 음료 전체 중량에서 산미료 0.1 내지 0.5 중량%, 감미료 3 내지 30중량% 함유되는 것이 바람직하다. 제조된 숙취해소 음료는 가열살균한 후 포장단계를 더 수행할 수 있음은 물론이다. And the hangover drink of the present invention may be further added acidulants and sweeteners. Citric acid, plum extract, etc. may be added as an acidulant, and xylitol, honey, concentrated pear juice may be added as a sweetener. In addition to the sweetener, various sweeteners may be used, such as a general beverage. It is preferable to contain 0.1 to 0.5% by weight of acidulant and 3 to 30% by weight of sweetener in the total weight of the hangover-relieving beverage. The hangover prepared drink can be further performed after the heat sterilization packaging step.
이하, 실험 예를 통하여 본 발명의 숙취해소 음료에 대해 설명하고자 한다. 다만, 하기의 실시 예는 본 발명을 구체적으로 설명하기 위한 것으로, 본 발명의 범위를 하기의 실시 예로 한정하는 것은 아니다.Hereinafter, the hangover drink of the present invention will be described through experimental examples. However, the following examples are intended to illustrate the present invention in detail, and the scope of the present invention is not limited to the following examples.
1. 노루 궁뎅이 버섯 추출실험1. roe deer mushroom extraction experiment
알코올분해효소 활성과 아세트알데하이드분해효소 활성을 증가시킬 수 있는 노루궁뎅이 버섯의 유효성분을 추출하기 위한 실험을 하였다. Experiments were performed to extract the active ingredient of the locust mushroom, which can increase the alcoholase and acetaldehyde activity.
노루궁뎅이버섯을 60℃에서 24시간 열풍 건조한 후 추출용매로 물을 이용하여 노루궁뎅이버섯 추출물을 얻었다. 이때 물의 양은 중량비로 노루궁뎅이 버섯의 30, 40, 50, 60배수로 하여 75℃와 100℃로 가열하였다. 그리고 추출과정 중에 원료의 유효성분 추출 정도를 예측하기 위해서 75℃로 가열시에는 4시간마다, 100℃로 가열시에는 0.5시간마다 추출물의 최종 수율, 가용성 고형분, pH, 총 당, 총 아미노산, 총 페놀을 조사하여 적정 추출조건을 찾고자 하였다. The roe deer mushroom extract was dried by hot air at 60 ° C. for 24 hours using water as an extraction solvent. At this time, the amount of water was heated to 75 ℃ and 100 ℃ to 30, 40, 50, 60 times the number of roe deer mushroom by weight ratio. The final yield, soluble solids, pH, total sugars, total amino acids, total amino acids of the extract every 4 hours when heated to 75 ℃ and 0.5 hours when heated to 100 ℃ to predict the degree of extraction of the active ingredient of the raw material during the extraction process Phenol was investigated to find the proper extraction conditions.
수율은 열수추출 전 초기 버섯중량과 용매중량의 합에 대한 추출물의 중량 백분율로 나타냈다. 가용성 고형분은 Hand refractometer(Atago N2, Japan)를, pH는 pH meter(Istek 915PDC, Korea)를 이용하여 측정하였다. 총 당은 phenol-H2SO4법에 의해 UV-spectrophotometer 490nm에서 흡광도를 측정하였다. 표준당은 maltose(Sigma Co,, USA)를 이용하였다. 총 아미노산은 닌히드린법에 의해 UV-spectrophotometer 570nm에서 흡광도를 측정하였고, 아미노산 표준품은 glutamic acid(Sigma Co., USA)를 이용하였다. 총 페놀은 Folin-Denies법으로 UV-spectrophotometer 760nm에서 흡광도를 측정하였고, 페놀 표준품은 ethyl gallate(Sigma Co., USA)를 이용하였다.Yield was expressed as weight percentage of the extract to the sum of the initial mushroom weight and the solvent weight before hot water extraction. Soluble solids were measured using a hand refractometer (Atago N2, Japan) and pH using a pH meter (Istek 915PDC, Korea). Total sugar was measured for absorbance at 490nm UV-spectrophotometer by phenol-H 2 SO 4 method. The standard sugar was maltose (Sigma Co, USA). Total amino acid was measured by the ninhydrin UV-spectrophotometer 570nm, the amino acid standard was used glutamic acid (Sigma Co., USA). Total phenol was measured by Folin-Denies method at 760 nm UV-spectrophotometer, and ethyl gallate (Sigma Co., USA) was used as a phenol standard.
도 1은 75℃에서 24시간 가열한 후 최종수율을 나타내는 그래프이고, 도 2는100℃에서 4시간 가열한 후 최종수율을 나타내는 그래프이다. 1 is a graph showing the final yield after heating for 24 hours at 75 ℃, Figure 2 is a graph showing the final yield after heating for 4 hours at 100 ℃.
도 1 및 도 2를 참조하면, 75℃에서 24시간 가열한 경우 용매의 혼합비율과 상관없이 최종 수율이 90% 전후로 나타났다. 이에 반해 100℃에서 4시간 가열한 경우 용매의 혼합비율에 따라 수율의 편차가 심하고, 최대치인 60배수에서 수율은 75℃에서 가열한 경우보다 현저하게 낮음을 알 수 있다. 100℃에서 추출한 경우에는 수율이 용매배수에 따라 32 내지 63% 정도인데 비해 75℃의 24시간 동안 추출하게 되면 수율이 90% 이상으로 높아 음료의 제조시 희석공정이 생략될 수 있어 음료제조에 더 유리할 것으로 판단된다. 1 and 2, the final yield was found to be around 90% regardless of the mixing ratio of the solvent when heated at 75
도 3은 75℃로 가열하여 4시간마다 가용성 고형분을 측정한 그래프이고, 도 4는 100℃로 가열하여 30분 마다 가용성 고형분을 측정한 그래프이다. 3 is a graph measuring the soluble solids every 4 hours by heating to 75 ℃, Figure 4 is a graph measuring the soluble solids every 30 minutes by heating to 100 ℃.
도 3 및 도 4를 참조하면, 75℃에서 추출한 경우 고형분은 용매의 배수가 낮을수록 더 높았으며 초기 추출물에서 24시간 동안 추출되는 시간에 따라 큰 변화 없이 완만한 증가를 보였다. 100℃에서 추출한 경우 용매 배수 30, 40의 경우에서는 가열시간이 지남에 따라 고형분이 크게 증가하였으나 50배 60배에서는 완만한 증가를 보였다. 3 and 4, when extracted at 75 ℃ solid content was higher the lower the drainage of the solvent and showed a gentle increase without significant change depending on the time extracted for 24 hours in the initial extract. In case of extraction at 100 ℃, solids increased significantly with heating time in the case of
도 5는 75℃로 가열하여 4시간마다 pH를 측정한 그래프이고, 도 6은 100℃로 가열하여 30분 마다 pH를 측정한 그래프이다. 5 is a graph measuring the pH every 4 hours by heating to 75 ℃, Figure 6 is a graph measuring the pH every 30 minutes by heating to 100 ℃.
도 5 및 도 6을 참조하면, 추출물의 pH는 용매의 배수가 낮을수록, 추출시간이 길어질수록 낮게 나타났으며, 75℃ 추출시 12시간 이전까지 급격히 감소하다가 그 이후에는 완만히 감소하였다. 5 and 6, the pH of the extract was lower the lower the drainage of the solvent, the longer the extraction time, the drastic decrease until 12 hours before the extraction at 75 ℃ and then slowly decreased.
도 7은 75℃로 가열하여 4시간마다 총 당을 측정한 그래프이고, 도 8은 100℃로 가열하여 30분 마다 총 당을 측정한 그래프이다. Figure 7 is a graph measuring the total sugar every 4 hours by heating to 75 ℃, Figure 8 is a graph measuring the total sugar every 30 minutes by heating to 100 ℃.
도 7 및 도 8을 참조하면, 75℃에서 추출한 경우 총 당은 용매의 배수가 낮을수록 가열시간이 길어짐에 따라 점진적으로 증가하는 경향을 보였으며 16시간 이후에는 변화가 거의 없거나 약간 증가하였으며, 100℃에서 추출한 경우 용매 배수가 낮을수록 가열시간이 지남에 따라 총 당이 크게 증가하였다. Referring to FIGS. 7 and 8, when extracted at 75 ° C., the total sugar showed a tendency to increase gradually as the heating time was longer as the drainage of the solvent was lower. After 16 hours, little or no change was observed , 100 In case of extraction at ℃, the lower the solvent drainage, the higher the total sugar was increased with the heating time.
도 9는 75℃로 가열하여 4시간마다 총 아미노산을 측정한 그래프이고, 도 10은 100℃로 가열하여 30분 마다 총 아미노산을 측정한 그래프이다. 9 is a graph measuring total amino acids every 4 hours by heating to 75 ℃, Figure 10 is a graph measuring the total amino acids every 30 minutes by heating to 100 ℃.
도 9 및 도 10을 참조하면, 75℃에서 추출한 경우 아미노산의 양은 용매의 배수가 낮을수록 더 높게 나타났으며, 가열시간 12시간까지 증가하다가 그 이후에는 거의 변화가 없거나 감소하는 경향으로 나타났다. 그리고 100℃에서 추출한 경우 용매 배수가 낮을수록 증가하였으며, 가열시간이 3시간까지 급격히 증가하다가 그 이후에는 완만히 증가하였다. 9 and 10, when extracted at 75 ℃ the amount of amino acids was higher the lower the drainage of the solvent, the higher the heating time up to 12 hours, after which almost no change or a tendency to decrease. And when extracted at 100 ℃ was increased the lower the solvent drainage, the heating time rapidly increased up to 3 hours and then slowly increased.
도 11은 75℃로 가열하여 4시간마다 총 페놀을 측정한 그래프이고, 도 12는 100℃로 가열하여 30분 마다 총 페놀을 측정한 그래프이다. FIG. 11 is a graph measuring total phenol every 4 hours by heating to 75 ° C, and FIG. 12 is a graph measuring total phenol every 30 minutes by heating to 100 ° C.
도 11 및 도 12를 참조하면, 페놀의 양은 용매의 배수가 낮을수록 약간 더 높게 나타났으나 가열시간 12시간 이후에는 거의 변화가 없었다. 그리고 100℃에서 추출한 경우 용매 배수가 낮을수록 가열시간이 지남에 따라 총 페놀량은 30배 용매배수인 경우는 크게 증가하였으나 40, 50, 60배 용매 배수인 경우는 75℃에서 추출한 경우와 거의 비슷한 함량으로 나타났다. 11 and 12, the amount of phenol was slightly higher as the drainage of the solvent was lower, but little change after 12 hours of heating time. In case of extraction at 100 ℃, the lower the solvent drainage, the greater the total phenol content was increased in the case of 30-fold solvent drainage as the heating time elapsed. Content.
상기의 결과들을 살펴보면 가용성 고형분, 총 당, 총 아미노산, 총 페놀, 항산화성은 100℃에서 추출한 것이 75℃에서 추출한 것보다 높게 나타났는데, 이는 100℃에서 추출하는 경우 추출과정에서 많은 수분이 증발되어 그만큼 농축되기 때문에 상대적으로 높게 나타난 것으로 보인다. The results of the above study showed that soluble solids, total sugar, total amino acid, total phenol, and antioxidant properties were higher than those extracted at 100 ° C than those extracted at 75 ° C. It appears to be relatively high because of its concentration.
그리고 노루궁뎅이 버섯 양의 40배 물을 첨가하여 75℃에서 24시간 추출한 추출물과 100℃에서 4시간 추출한 추출물의 유기물 및 무기물의 함량, 그리고 무기질의 함량을 하기 표4 및 표 5에 각각 나타냈다. And the content of organic and inorganic materials, and the mineral content of the extract extracted at 75 ℃ for 24 hours and the extract extracted at 100 ℃ for 4 hours by adding
상기 표7에서, 유기물 함량은 수분과 무기물을 제외한 중량 백분율로 나타냈고, 무기물은 시료를 600℃에서 3시간 태운 후 남은 재의 중량을 초기 추출물 중량 백분율로 나타낸 것으로, 유기물과 무기물 함량 모두 75℃에서 추출한 것이 100℃에서 추출한 것보다 더 높음을 알 수 있다. In Table 7, the organic content is expressed as a weight percentage excluding moisture and inorganic matters, and the inorganic material indicates the weight of ash remaining after burning the sample at 600 ° C. for 3 hours as an initial extract weight percentage, and both the organic and inorganic content at 75 ° C. It can be seen that the extraction is higher than that extracted at 100 ° C.
상기 표 8에서, 도 14는 75℃와 100℃에서 추출한 것의 무기질 Na, Mg, Ca, Zn, Mn, P, Fe, K 함량을 나타낸 것으로 75℃로 추출한 것의 함량이 전체적으로 더 높았다.In Table 8, Figure 14 shows the inorganic Na, Mg, Ca, Zn, Mn, P, Fe, K content of those extracted at 75 ℃ and 100 ℃, the content of the extracted at 75 ℃ was higher overall.
2. ADH 및 ALDH 활성실험2. ADH and ALDH Activity Test
노루궁뎅이버섯 추출물과 시중 숙취해소 음료의 ADH 및 ALDH의 활성을 비교실험하였다. 노루궁뎅이버섯 추출물은 노루궁뎅이 버섯 양의 40배 물을 첨가하여 75℃에서 24시간 추출한 추출물과 100℃에서 4시간 추출한 추출물, 그리고 시중에서 판매하는 숙취해소음료 4가지의 알코올분해효소(alcohol dehydrogenase, ADH)의 활성 및 아세트알데하이드분해효소(aldehyde dehydrogenase, ALDH)의 활성을 비교하여 그 결과를 도 13 및 도 14에 각각 나타내었다. The activities of ADH and ALDH were compared between the extracts of roe deer fungus extract and hangover. The extract of the extract was extracted 24 hours at 75 ° C for 24 hours, 4 hours at 100 ° C, and four hangover anti-alcoholic enzymes (alcohol dehydrogenase, The activity of ADH) and the activity of acetaldehyde dehydrogenase (ALDH) were compared and the results are shown in FIGS. 13 and 14, respectively.
시료의 ADH 활성은 Choi등과 Racker의 방법을 이용하여 UV-spectrophotometer(Jasco-Y550)를 이용하여 340nm에서 형성되는 NADH의 흡광도를 측정하였다. ADH 활성의 최적 조건을 알아낸 후, ADH 활성이 직선을 나타내는 반응시간과 효소농도에서 최고 값의 시험관에 알코올 0.2mL, NAD 수용액(2mg/mL) 1mL, 숙취해소효능평가할 시료 0.2mL, 0.05M tris-HCl buffer (pH 8.8) 2.2mL를 넣어 총 부피가 3.6mL이 되게 한 후 25℃ 항온 수조에서 10분간 반응시키고 ADH(18 units/mL) 0.5mL를 가하여 340nm에서 흡광도의 변화를 측정하였다. 대조구는 ADH 대신 0.01M glycine-NaOH 완충액 0.25mL를 넣는다. 반응이 끝나면 즉시 시험관을 얼음에 옮긴 후 위의 spectrophotometer를 이용해 340nm에서 ADH의 활성을 측정하였다. ADH 활성은 반응 종료시의 최대 흡광도를 대조구의 최대 흡광도에 대한 비율로 나타냈다. 실험에 사용된 모든 시약 및 효소는 순도 90% 이상의 Sigma 사에서 구입한 제품이다. The ADH activity of the samples was measured by absorbing NADH formed at 340 nm using a UV-spectrophotometer (Jasco-Y550) using Choi et al. And Racker's method. After determining the optimal conditions for ADH activity, 0.2 mL of alcohol, 1 mL of NAD aqueous solution (2 mg / mL), 0.2 mL of sample to be analyzed for hangover efficacy, 0.05M 2.2 mL of tris-HCl buffer (pH 8.8) was added to make the total volume 3.6 mL, followed by reaction for 10 minutes in a 25 ° C. constant temperature water bath, and 0.5 mL of ADH (18 units / mL) was added to measure the change in absorbance at 340 nm. For the control, 0.25 mL of 0.01M glycine-NaOH buffer was added instead of ADH. Immediately after the reaction, the test tube was transferred to ice, and the activity of ADH was measured at 340 nm using the spectrophotometer. ADH activity indicated the maximum absorbance at the end of the reaction as a ratio to the maximum absorbance of the control. All reagents and enzymes used in the experiment were purchased from Sigma with a purity of 90% or higher.
ADH activity = B/A×100 ADH activity = B / A × 100
A:대조구의 최대 흡광도, B:실험구의 최대 흡광도A: maximum absorbance of the control, B: maximum absorbance of the test
시료의 ALDH의 활성은 Hawang 등과 Tottmar 등의 방법을 변형하여 실험하였으며, 생성된 NADH 흡광도를 340nm에서 측정하였다. ALDH의 활성도 측정을 위해 50mM sodium pyrophosphate 완충용액(pH8.8)에 0.5mM NAD, 0.1mM pyrazole, 5mM acetaldehyde인 반응액 2.25mL에 0.1mL ALDH(1unit/mL)을 넣고 숙취해소효능평가할 시료 0.2mL 씩 첨가한 후 37℃ water bath에서 10분간 방치하고 340nm에서 흡광도를 측정하였다.The ALDH activity of the sample was tested by modifying the methods of Hawang and Tottmar, etc., and the resulting NADH absorbance was measured at 340 nm. To measure the activity of ALDH, add 0.1 mL ALDH (1 unit / mL) to 2.25 mL of 0.5 mM NAD, 0.1 mM pyrazole, and 5 mM acetaldehyde in 50 mM sodium pyrophosphate buffer solution (pH8.8). After each addition, it was left for 10 minutes in a 37 ℃ water bath and the absorbance was measured at 340nm.
도 13 및 도 14를 참조하면, 노루궁뎅이 버섯 추출물이 시중의 4가지 숙취해소음료보다 ADH 및 ALDH의 활성이 더 우수한 것을 알 수 있다. 그리고 75℃에서 24시간 추출한 경우가 100℃에서 4시간 추출한 경우보다 ADH 및 ALDH의 활성이 더 높았다. Referring to Figure 13 and 14, it can be seen that the extract of the Roerung beetle mushroom has more excellent activity of ADH and ALDH than the four hangover drinks on the market. In addition, ADH and ALDH activities were higher when extracted at 75 ° C. for 24 hours than when extracted at 100 ° C. for 4 hours.
ADH 및 ALDH의 활성효과는 가용성 고형분, 총당, 총페놀 등의 함량보다는 비타민 B1, B2, 나이아신, 무기질등이 영향을 미치는 것으로 추정된다. 이러한 비타민 B1, B2, 나이아신, 무기질 등은 고온에 약하므로 비교적 낮은 온도에서 추출하는 것이 바람직하다. 그리고 노루궁뎅이버섯은 균체로서 불활성화시키면서 유효성분을 추출해야하므로 추출온도는 65℃ 이상인 것이 바람직하다. The active effects of ADH and ALDH may be attributed to vitamins B1, B2, niacin, and minerals, rather than soluble solids, total sugars, and total phenols. Since vitamin B1, B2, niacin, minerals, etc. are weak to high temperature, it is preferable to extract at a relatively low temperature. In addition, since the extract of the active ingredient must be extracted while inactivated as a bacterium, the extract temperature is preferably at least 65 ℃.
따라서 중량비가 30 내지 60이 되도록 혼합한 후 65 내지 85℃에서 16 내지 24시간 동안 가열하여 추출하는 추출기술이 적용된 본 발명의 숙취해소음료는 ADH 및 ALDH 활성이 시중 숙취해소 음료보다 1.5~2배 더 높아 알코올 대사를 촉진시켜 혈중 알코올 농도를 효과적으로 감소시킬 것으로 기대된다. Therefore, the hangover beverage of the present invention to which the extraction technique is applied by extracting by mixing the weight ratio of 30 to 60 after heating at 65 to 85 ℃ for 16 to 24 hours, ADH and ALDH activity 1.5 ~ 2 times than the commercial hangover beverage Higher levels are expected to promote alcohol metabolism, effectively reducing blood alcohol levels.
(실시예)(Example)
노루궁뎅이 버섯, 민들레, 구기자, 사철쑥을 60℃에서 24시간 열풍 건조하여 추출할 재료들을 준비하였다. 그리고 곱게 빻은 엿기름 분말을 냉수에 풀어서 3시간 동안 우련 낸 후 맑은 상층수를 얻었다. 준비된 노루궁뎅이버섯, 민들레, 구기자, 사철쑥의 혼합물의 중량 150g에 상기 상층수 6kg을 혼합한 후 75℃에서 24시간 동안 가열 추출하였다. 이때 노루궁뎅이 버섯, 민들레, 구기자, 사철쑥의 혼합비율은 하기 표 6과 같다.Roe deer mushroom, dandelion, goji berry, cedar mugwort were prepared by hot-air drying for 24 hours at 60 ℃. Then, finely ground malt powder was dissolved in cold water, and then starved for 3 hours to obtain clear supernatant. 6 kg of the supernatant was mixed with 150 g of the mixture of the prepared roe deer mushroom, dandelion, wolfberry, and cedar, and heat-extracted at 75 ° C. for 24 hours. At this time, the mixing ratio of the roe deer mushroom, dandelion, gojija, cedars is as shown in Table 6.
그리고 상기 추출물에 맛 버섯 추출물 및 산미료, 감미료를 첨가하였다. 이때 혼합비율은 하기 표 7과 같다. And to the extract was added taste mushroom extract, acidulant, sweetener. At this time, the mixing ratio is as shown in Table 7 below.
맛 버섯 추출물 및 산미료, 감미료를 첨가한 후 100℃ 5분간 가열살균하여 본 발명의 숙취해소 음료를 제조하였다. Taste mushroom extract, acidulant, sweetener was added and then sterilized by heating for 5 minutes at 100 ℃ to prepare a hangover solution of the present invention.
상기의 실시 예에 따라 제조된 숙취해소음료의 수율, 성분, 항산화성, ADH활성도, ALDH활성도는 하기 표 8과 같이 나타났다. Yields, ingredients, antioxidant properties, ADH activity, ALDH activity of the hangover drink prepared according to the above embodiment was shown in Table 8.
본 발명의 추출방법 및 조성물에 의한 알코올디하이드로겐에이스(ADH)와 아세트알데하이드디하이드로겐에이스(ALDH) 활성을 조사했을 때 시중 숙취해소 음료보다 1.5~2배 더 높은 활성을 나타내며, 본 발명에 의해 제조된 숙취해소음료에 첨가되는 성분의 효능으로서 맛 버섯은 알코올 흡수를 억제하며, 노루궁뎅이버섯은 알코올 대사를 촉진시켜 혈중 알코올 농도를 감소시키며, 구기자, 민들레, 사철쑥은 알코올로부터 간세포를 보호하고, 맛 버섯은 위장점막을 도포함으로써 알코올 흡수 방지 또는 속쓰림의 예방 또는 치료에 있다.When the alcohol dihydrogen ace (ADH) and acetaldehyde dihydrogen ace (ALDH) activity by the extraction method and composition of the present invention was investigated, it exhibited 1.5 to 2 times higher activity than the commercial hangover beverage. As a potency of the ingredient added to hangover quenching drinks, taste mushrooms inhibit alcohol absorption, and locust mushrooms promote alcohol metabolism to reduce blood alcohol concentration, and wolfberry, dandelion and cedar fungus protect liver cells from alcohol. Taste mushrooms are in the prevention of alcohol absorption or in the prevention or treatment of heartburn by applying gastrointestinal mucosa.
이상에서 본 발명은 일 실시 예를 참고로 설명되었으나 이는 예시적인 것에 불과하며, 당해 기술분야에서 통상의 지식을 가진 자라면 이로부터 다양한 변형 및 균등한 실시 예가 가능하다는 점을 이해할 것이다.While the present invention has been described with reference to exemplary embodiments, it is to be understood that the invention is not limited to the disclosed exemplary embodiments.
따라서 본 발명의 진정한 보호 범위는 첨부된 청구범위에 의해서만 정해져야 할 것이다.Therefore, the true scope of protection of the present invention should be defined only by the appended claims.
도 1은 75℃에서 24시간 가열한 후 최종수율을 나타내는 그래프이고, 도 2는100℃에서 4시간 가열한 후 최종수율을 나타내는 그래프이다. 1 is a graph showing the final yield after heating for 24 hours at 75 ℃, Figure 2 is a graph showing the final yield after heating for 4 hours at 100 ℃.
도 3은 75℃로 가열하여 4시간마다 가용성 고형분을 측정한 그래프이고, 도 4는 100℃로 가열하여 30분 마다 가용성 고형분을 측정한 그래프이다. 3 is a graph measuring the soluble solids every 4 hours by heating to 75 ℃, Figure 4 is a graph measuring the soluble solids every 30 minutes by heating to 100 ℃.
도 5는 75℃로 가열하여 4시간마다 pH를 측정한 그래프이고, 도 6은 100℃로 가열하여 30분 마다 pH를 측정한 그래프이다. 5 is a graph measuring the pH every 4 hours by heating to 75 ℃, Figure 6 is a graph measuring the pH every 30 minutes by heating to 100 ℃.
도 7은 75℃로 가열하여 4시간마다 총 당을 측정한 그래프이고, 도 8은 100℃로 가열하여 30분 마다 총 당을 측정한 그래프이다. Figure 7 is a graph measuring the total sugar every 4 hours by heating to 75 ℃, Figure 8 is a graph measuring the total sugar every 30 minutes by heating to 100 ℃.
도 9는 75℃로 가열하여 4시간마다 총 아미노산을 측정한 그래프이고, 도 10은 100℃로 가열하여 30분 마다 총 아미노산을 측정한 그래프이다. 9 is a graph measuring total amino acids every 4 hours by heating to 75 ℃, Figure 10 is a graph measuring the total amino acids every 30 minutes by heating to 100 ℃.
도 11은 75℃로 가열하여 4시간마다 총 페놀을 측정한 그래프이고, 도 12는 100℃로 가열하여 30분 마다 총 페놀을 측정한 그래프이다. FIG. 11 is a graph measuring total phenol every 4 hours by heating to 75 ° C, and FIG. 12 is a graph measuring total phenol every 30 minutes by heating to 100 ° C.
도 13 및 도 14는 알코올알코올효소의 활성 및아세트알데하이드분해효소의 활성을 나타낸 그래프이다.13 and 14 are graphs showing the activity of alcohol alcoholase and the activity of acetaldehydease.
Claims (4)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020090026609A KR101082598B1 (en) | 2009-03-27 | 2009-03-27 | Hangover recovery drink comprising extracts of Hericium Erinaceum |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020090026609A KR101082598B1 (en) | 2009-03-27 | 2009-03-27 | Hangover recovery drink comprising extracts of Hericium Erinaceum |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20100108112A true KR20100108112A (en) | 2010-10-06 |
KR101082598B1 KR101082598B1 (en) | 2011-11-10 |
Family
ID=43129735
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020090026609A KR101082598B1 (en) | 2009-03-27 | 2009-03-27 | Hangover recovery drink comprising extracts of Hericium Erinaceum |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR101082598B1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101320543B1 (en) * | 2013-04-26 | 2013-10-28 | 이대희 | Cereal containing hericium erinaceus and manufacturing process of the same |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102637880B1 (en) | 2021-07-26 | 2024-02-19 | 김인자 | Manufacturing method of Wagashi using Blueberry |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100624101B1 (en) * | 2004-02-06 | 2006-09-18 | 주식회사 코시스바이오 | Composition for enhancing alcohol decomposition containing extract from hericicum erinaceus |
KR100660175B1 (en) * | 2005-02-25 | 2006-12-21 | 김덕현 | Composition in drink to get rid of hangover |
-
2009
- 2009-03-27 KR KR1020090026609A patent/KR101082598B1/en active IP Right Grant
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101320543B1 (en) * | 2013-04-26 | 2013-10-28 | 이대희 | Cereal containing hericium erinaceus and manufacturing process of the same |
WO2014175545A1 (en) * | 2013-04-26 | 2014-10-30 | Lee Dae-Hee | Cereal containing hericium erinaceum and method for making same |
US9623060B2 (en) | 2013-04-26 | 2017-04-18 | Dae-hee Lee | Cereal containing hericium erinaceum and method for making same |
Also Published As
Publication number | Publication date |
---|---|
KR101082598B1 (en) | 2011-11-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR100661032B1 (en) | Composition for Improving Liver Function, Reduction of Serum Ethanol Level, and Antioxidation | |
KR101183605B1 (en) | The beverage composition for anti-hangover functional using cucumber vinegar | |
KR101301094B1 (en) | Composition for relieving hangover or improving liver function | |
KR20140090453A (en) | Composition comprising aronia extract for preventing and relieving hangover, and for protecting the alcohol-damaged hepatocyte | |
KR20130041565A (en) | The beverage comprising sap for curing hangover and manufacturing method thereof | |
CN108404019A (en) | Compound chicory root adjusts the solid articles and preparation method thereof of purine metabolic disturbance | |
KR101548340B1 (en) | Hangover recovery drink using bean sprouts and manufacturing method thereof | |
KR101614929B1 (en) | A pharmaceutical composition for treating cognitive and memory impairment | |
KR101588378B1 (en) | Method for manufacturing hangover curing agent and hangover curing agent manufactured by the same | |
KR101082598B1 (en) | Hangover recovery drink comprising extracts of Hericium Erinaceum | |
KR101371143B1 (en) | Composition comprising chlorella for improving liver function or relieving hangover | |
KR101819026B1 (en) | Composition for use of inhibition of stomach damage to alcohol or inhibition of alcohol uptake or relief of hangover comprising fermented extract of native plants from Jeju island | |
KR100767802B1 (en) | Functional beverage containing persimmon vinegar | |
KR101838576B1 (en) | Fermented Lespedeza cuneata extract and its manufacturing method and drink containing it | |
KR20190044166A (en) | Process for producing antioxidant and anti-fatigue efficacy of mulberry vinegar | |
CN114451562B (en) | Hovenia dulcis thunb, radix puerariae and corn oligopeptide composition, beverage and preparation method thereof | |
KR101034986B1 (en) | Composition comprising the mixed herbal extract for relieving hangover | |
KR20110118911A (en) | Lactic acid bacteria fermented extract using cereals and herb medicine materials, and method of preparing thereof | |
KR101061219B1 (en) | Composition containing extract of jerusalem artichoke fermented by lactobacillus sp. for preventing and treating diabetes mellitus | |
CN112690385B (en) | Low-glycemic pitaya juice and preparation method thereof | |
KR102155057B1 (en) | Food Composition for blood circulation and preventing blood vessel disease Comprising red ginseng and nitric oxide solution and its manufacturing method | |
KR20150057108A (en) | Drinking composition comprising Ginseng extract and Rosted Grain Extract | |
KR20140017933A (en) | Composition comprising fermented extract of trifoliate orange for improving diabetes | |
KR102127411B1 (en) | Composition comprising natural complex extract for protecting liver and relieving hangover | |
KR101925124B1 (en) | Manufacturing method for fermented drink using vegetable sourse |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20141023 Year of fee payment: 4 |
|
FPAY | Annual fee payment |
Payment date: 20150820 Year of fee payment: 5 |
|
FPAY | Annual fee payment |
Payment date: 20170912 Year of fee payment: 7 |
|
FPAY | Annual fee payment |
Payment date: 20181018 Year of fee payment: 8 |
|
FPAY | Annual fee payment |
Payment date: 20191002 Year of fee payment: 9 |